tiprankstipranks
Revance Therapeutics Renews Manufacturing Deal and Announces Executive Transition
Company Announcements

Revance Therapeutics Renews Manufacturing Deal and Announces Executive Transition

Don't Miss our Black Friday Offers:

The latest update is out from Revance Therapeutics (RVNC).

Revance Therapeutics, Inc. has extended its agreement with Ajinomoto Bio-Pharma Services until December 31, 2027, for manufacturing services related to DAXXIFY® at their San Diego facility, with updated terms regarding product conformity and delay remedies. Additionally, the company’s President, Mr. Sjuts, will step down, receiving a severance package, which includes 18 months of his base salary and health benefits, and will remain as a consultant for a year to ensure a smooth transition and allow his equity awards to continue vesting.

For an in-depth examination of RVNC stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyNvidia trades on Dow for first time, Rivian reports downbeat Q3: Morning Buzz
TipRanks Auto-Generated NewsdeskRevance Therapeutics Reports Q3 Growth Amid Merger Plans
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App